SANOFI-AVENTIS (EPA:SAN)

PRESS RELEASE

published on 10/09/2024 at 07:00, 1 month 14 days ago

Press Release: New Beyfortus data featured at IDWeek reinforce real-world effectiveness against RSV disease and hospitalization in infants
Sanofi presents new Beyfortus data at IDWeek 2024, showcasing real-world effectiveness in protecting infants from RSV disease and hospitalization. Beyfortus doses shipped for 2024-2025 RSV season

Sanofi RSV Beyfortus Infants IDWeek
BRIEF

published on 09/27/2024 at 15:40, 1 month 25 days ago

Dupixent Approved in the US as First Biologic for COPD Patients

FDA Approval Clinical Studies COPD Dupixent Biologic Medicine
PRESS RELEASE

published on 09/27/2024 at 15:35, 1 month 25 days ago

Press Release: Dupixent approved in the US as the first-ever biologic medicine for patients with COPD
US FDA approves Dupixent as the first-ever biologic medicine for COPD, based on phase 3 studies showing significant reduction in exacerbations and improved lung function. Dupixent is now leading in new-to-brand prescriptions for FDA-approved indications

FDA Approval Dupixent COPD Treatment Biologic Medicine Phase 3 Studies
BRIEF

published on 09/27/2024 at 13:05, 1 month 25 days ago

Dupixent Authorized in China as First Biologic Medicine for COPD Patients

China Approval COPD Dupixent Biologic Medicine
PRESS RELEASE

published on 09/27/2024 at 13:00, 1 month 25 days ago

Press Release: Dupixent approved in China as the first-ever biologic medicine for patients with COPD
Dupixent approved in China as the first-ever biologic medicine for COPD patients, following landmark phase 3 studies. Approval crucial for addressing COPD burden in China

China COPD Dupixent Biologic Medicine Phase 3 Studies
BRIEF

published on 09/21/2024 at 00:41, 2 months 2 days ago

Sarclisa Approved in the United States for the Treatment of Multiple Myeloma

FDA Sanofi Multiple Myeloma Sarclisa First Line Treatment
BRIEF

published on 09/20/2024 at 13:50, 2 months 2 days ago

CHMP recommends approval of Dupixent for children aged 12 months and older

Children Medicine Dupixent CHMP Esophagitis
PRESS RELEASE

published on 09/20/2024 at 13:45, 2 months 2 days ago

Press Release: Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old
Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old based on positive phase 3 study results. Dupixent would be the first medicine indicated for EoE in this age group

Children Dupixent CHMP EU Approval Eosinophilic Esophagitis
BRIEF

published on 09/20/2024 at 11:35, 2 months 2 days ago

Sanofi's Tolebrutinib Shows Promise in Delaying Disability Progression in MS

Multiple Sclerosis ECTRIMS 2024 Tolebrutinib HERCULES Study Disability Progression
PRESS RELEASE

published on 09/20/2024 at 11:30, 2 months 2 days ago

Press Release: Tolebrutinib demonstrated a 31% delay in time to onset of confirmed disability progression in non-relapsing secondary progressive multiple sclerosis phase 3 study
Study shows tolebrutinib delays disability progression in non-relapsing secondary progressive MS by 31%; global regulatory submissions in H2 2024. ECTRIMS 2024 data presented

ECTRIMS 2024 Tolebrutinib Disability Progression Secondary Progressive MS Global Regulatory Submissions

Published on 11/22/2024 at 23:55, 10 hours 35 minutes ago

Boron One Announces Early Warrant Exercise Incentive Program
Published on 11/22/2024 at 23:30, 11 hours ago

Electric Royalties Enters Into Definitive Agreement to Acquire 0.75% Gross Revenue Royalty on Producing Punitaqui Copper Mine in Chile
Published on 11/22/2024 at 23:05, 11 hours 25 minutes ago

Kidoz Inc. Announces Results of 2024 AGM
Published on 11/22/2024 at 23:05, 11 hours 25 minutes ago

Nexa Resources Announces Closing Transaction of Pukaqaqa Project Sale to Olympic
Published on 11/22/2024 at 22:30, 12 hours ago

Delaforce Energy Corp. Announces Acquisition of Bouchard Well Service Ltd.

View all ACCESSWIRE

Published on 11/22/2024 at 18:14, 16 hours 15 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 11/22/2024 at 18:00, 16 hours 30 minutes ago

Holding(s) in Company
Published on 11/22/2024 at 17:53, 16 hours 36 minutes ago

Funding Circle Plc: POS-Transaction in Own Shares
Published on 11/22/2024 at 16:55, 17 hours 34 minutes ago

EQS-Adhoc: Comment on withdrawn non-binding offer
Published on 11/22/2024 at 16:00, 18 hours 30 minutes ago

Proposed cancellation of admission to trading

View all EQS

Published on 11/22/2024 at 14:35, 19 hours 55 minutes ago

Thales Press release
Published on 11/21/2024 at 06:58, 2 days 3 hours ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 2 days 15 hours ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 2 days 16 hours ago

MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 2 days 16 hours ago

Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024

View all LES ECHOS COMFI WIRE

News